Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

Summary

This pilot study will assess the impact of sacubitril/valsartan (trade name Entresto) on the elevated pulmonary artery pressures in patients with heart failure with reduced ejection fraction, measured using a previously implanted hemodynamic monitoring device (CardioMEMS).

Timeline

Start

2016-09

Primary completion

2018-11-09

Completion

2018-11-09

Outcome

Outcome not reported

Stopped (Enrollment): “Inadequate Recruitment”

Drugs

Indications